The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...
Weight loss drugs like Ozempic and Wegovy have seemingly taken over this year, curbing users appetites by making them feel ...
Independence Blue Cross said starting Jan. 1 it will only be covering GLP-1 agonists — commonly sold under brand names like ...
The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity ...
Explore the world of weight loss drugs. Find out how GLP-1-based drugs can lead to significant weight loss, but also bone and ...
Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback